Form 4: Cero Therapeutics Holdings Director Acquires Stock Options
SEC Form 4 Filing
Director Lindsey Rolfe acquired stock options for 17,923 shares of Cero Therapeutics Holdings on March 4, 2025.
Summary
- Lindsey Rolfe, a director of Cero Therapeutics Holdings, acquired stock options on March 4, 2025.
- The transaction involved the acquisition of options to purchase 17,923 shares of common stock.
- These options have an exercise price of $1.43.
- The options vest over time, with 50% vesting on the twelve-month anniversary of the grant date and the remaining portion subject to performance conditions.
- Following the transaction, Rolfe directly owns options for 17,923 shares.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing, so the sentiment is neutral.
Industry Context
This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership by a company insider. Such filings are common and provide transparency into the trading activities of company directors and officers.
Stakeholder Impact
- The transaction provides transparency to shareholders regarding insider activity.
Key Dates
| Date | Description |
|---|---|
| 03/04/2025 | Date of the stock option transaction |
| 03/06/2025 | Date of signature on the Form 4 filing |
| 03/03/2035 | Expiration date of the stock options |
Keywords
Stock Options, Form 4, Director, Cero Therapeutics Holdings, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.